Roth MKM lowered the firm’s price target on Franklin Covey to $65 from $71 after its Q2 earnings miss but keeps a Buy rating on the shares. The company’s near-term headwinds will push out its anticipated revenue growth acceleration and this could limit near-term upside for shares, but the downside also appears limited given the current valuation of 11-times expected FY23 and 9-times expected FY24 EBITDA, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FC: